Physician profile
Mohammad Islam
NPI 1811992878
$1,905.28
in general payments reported to CMS, 2019-2025
24 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $150 · 2021: $93.73 · 2022: $90.42 · 2023: $362 · 2024: $394 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $250.00 | 2019 | |
| Endo Pharmaceuticals INC. | $242.40 | 2019-2024 | Xiaflex |
| Endo USA, INC. | $229.07 | 2024-2025 | Xiaflex |
| Leo Pharma INC. | $196.99 | 2023-2025 | Adbry, Spevigo |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Abbvie INC. | $147.61 | 2023-2025 | |
| Incyte Corporation | $94.58 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $94.00 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $75.84 | 2023-2025 | Tremfya |
| Dilon Technologies, INC. | $60.18 | 2025 | Hemoblast Bellows |
| Solventum Corporation | $46.88 | 2024 | Promogran Prisma, Activ.A.C. |
| Musculoskeletal Transplant Foundation INC. | $43.39 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $38.53 | 2021-2023 | Absorica Ld, Winlevi |
| Tela Bio, INC. | $34.56 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Sonex Health, INC. | $33.64 | 2022-2024 | Sx-One Microknife |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.43 | 2021-2022 | |
| Smith+Nephew, INC. | $29.22 | 2023 | Grafix, Stravix |
| Glaxosmithkline, LLC. | $19.54 | 2024 | Nucala |
| Integra Lifesciences Corporation | $16.90 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Innovation Technologies INC | $15.66 | 2025 | Irrisept |
| Acelrx Pharmaceuticals, INC. | $15.65 | 2021 | |
| Genentech USA, INC. | $14.84 | 2021 | |
| Genzyme Corporation | $14.78 | 2025 | |
| Baudax Bio INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.